Dermatologic toxicities of antibody-drug conjugates

Area of Science:

• Oncology
• Dermatology
• Pharmacology

Background:

• Antibody-drug conjugates (ADCs) represent an emerging class of cancer therapeutics.
• ADCs combine monoclonal antibodies for targeted delivery with cytotoxic payloads.
• Over 80 ADCs are in clinical development, highlighting their growing importance.

Purpose of the Study:

• To review the mechanisms and indications of approved ADCs.
• To summarize the cutaneous toxicities associated with ADCs.
• To provide guidance on recognizing and managing these dermatologic adverse events.

Main Methods:

• Clinical review of approved ADCs and their associated toxicities.
• Analysis of data from clinical trials and postmarketing studies.
• Synthesis of current knowledge on ADC mechanisms and dermatologic side effects.

Main Results:

• ADCs exhibit diverse mechanisms of action and indications for various cancers.
• Unique and agent-specific cutaneous toxicities are frequently observed with ADCs.
• Effective management strategies are crucial for patient tolerance and adherence.

Conclusions:

• Dermatologists play a critical role in managing ADC-related skin toxicities.
• Early recognition and appropriate intervention can mitigate adverse events.
• This review provides essential guidance for clinicians managing patients on ADC therapy.